RS34004A - Methods and compositions of novel triazine compounds - Google Patents

Methods and compositions of novel triazine compounds

Info

Publication number
RS34004A
RS34004A YU34004A YUP34004A RS34004A RS 34004 A RS34004 A RS 34004A YU 34004 A YU34004 A YU 34004A YU P34004 A YUP34004 A YU P34004A RS 34004 A RS34004 A RS 34004A
Authority
RS
Serbia
Prior art keywords
compounds
present
compositions
smooth muscle
methods
Prior art date
Application number
YU34004A
Other languages
Serbian (sr)
Inventor
Richard Timmer
Christopher Alexander
Sivaram Pillarisetti
Uday Saxena
Karen Campbell
Original Assignee
Reddy Us Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc. filed Critical Reddy Us Therapeutics Inc.
Publication of RS34004A publication Critical patent/RS34004A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Abstract

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.
YU34004A 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds RS34004A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32414701P 2001-09-21 2001-09-21
PCT/US2002/030177 WO2003024926A2 (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Publications (1)

Publication Number Publication Date
RS34004A true RS34004A (en) 2006-10-27

Family

ID=23262298

Family Applications (1)

Application Number Title Priority Date Filing Date
YU34004A RS34004A (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Country Status (16)

Country Link
EP (1) EP1436266A4 (en)
JP (1) JP2005511509A (en)
KR (1) KR20040088457A (en)
CN (1) CN1578773A (en)
BR (1) BR0212895A (en)
CA (1) CA2461074A1 (en)
EA (1) EA009728B1 (en)
IL (1) IL160984A0 (en)
IS (1) IS7190A (en)
MX (1) MXPA04002680A (en)
NO (1) NO20041187L (en)
NZ (1) NZ532349A (en)
PL (1) PL369600A1 (en)
RS (1) RS34004A (en)
WO (1) WO2003024926A2 (en)
ZA (1) ZA200403009B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
ATE511858T1 (en) 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
AU2003253735A1 (en) * 2002-06-25 2004-01-06 The Center For Blood Research, Inc. Vacuolins
US20070161637A1 (en) * 2003-07-22 2007-07-12 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CN1629157A (en) * 2003-12-19 2005-06-22 中国科学院上海药物研究所 Piperazinyl triazine compounds, preparation method thereof and pharmaceutical composition containing same
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
CA2668363A1 (en) * 2006-11-03 2008-05-08 Nerviano Medical Sciences S.R.L. A method of administering an antitumor compound
KR101314869B1 (en) * 2010-07-29 2013-10-04 광주과학기술원 Pharmaceutical Compositions for Treating or Preventing Diabetes Comprising Triazine Compound as an Active Ingredient
SG190921A1 (en) * 2010-11-29 2013-07-31 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
CA3009510A1 (en) 2015-12-24 2017-06-29 The Regents Of The University Of California Phenylamino-1,3,5- triazine derivatives and use thereof as cftr regulators
WO2019040919A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California Ocular pharmaceutical compositions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083568C1 (en) * 1994-05-05 1997-07-10 Кубанский государственный аграрный университет Triazinecarboxylic acid salts and agent for presowing treatment of agriculture crop seeds
DE19531084A1 (en) * 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-diamino-1,3,5-triazines, process for their preparation and their use as herbicides and plant growth regulators
IL136339A0 (en) * 1997-12-12 2001-05-20 Abbott Lab Triazine angiogenesis inhibitors
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
WO2001047921A1 (en) * 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20040088457A (en) 2004-10-16
JP2005511509A (en) 2005-04-28
EP1436266A2 (en) 2004-07-14
PL369600A1 (en) 2005-05-02
EA009728B1 (en) 2008-02-28
WO2003024926A3 (en) 2003-12-11
EP1436266A4 (en) 2004-12-22
BR0212895A (en) 2005-05-10
EA200400464A1 (en) 2005-02-24
ZA200403009B (en) 2007-12-27
NO20041187L (en) 2004-05-19
WO2003024926A2 (en) 2003-03-27
MXPA04002680A (en) 2004-06-18
CN1578773A (en) 2005-02-09
CA2461074A1 (en) 2003-03-27
NZ532349A (en) 2007-02-23
IL160984A0 (en) 2004-08-31
IS7190A (en) 2004-03-19

Similar Documents

Publication Publication Date Title
RS34004A (en) Methods and compositions of novel triazine compounds
ATE190978T1 (en) 6-ARYL-PYRIDO(2,3-D)PYRIMIDINES AND NAPHTHYRIDINES FOR INHIBITING CELL PRODUCTION CAUSED BY PROTEIN TYROSINE KINASE
MXPA04000622A (en) Pyrazolylcarboxanilides as fungicides.
WO2001025238A3 (en) Heterocyclic compounds useful as inhibitors of tyrosine kinases
DE60311662D1 (en) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
AU2735201A (en) Pyrimidine and triazine kinase inhibitors
RS51445B (en) Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors
ATE450515T1 (en) ANILINOPYRIMIDENE DERIVATIVES AS IC INHIBITORS, AND RELATED COMPOSITIONS AND METHODS
WO2002103103A3 (en) Fluorine-containing compounds and polymers derived therefrom
WO2003018758A3 (en) Reagents and methods for smooth muscle therapies
WO2005042712A3 (en) Heterocyclic compounds and methods of making and using thereof
MXPA03010269A (en) 2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors.
DE60228878D1 (en) PROTEINS WITH IL-6 INHIBITORAL EFFECT
RS19504A (en) Novel compounds and compositions as cathepsin inhibitors
ATE315029T1 (en) 6-ARYLPHENANTHRIDINE WITH PDE-IV INHIBITING EFFECT
AU2001265828A1 (en) Steeping process
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
DE60225155D1 (en) 3-SUBSTITUTED 6,7-DIHYDROXYTETRAHYDROISOCHINOLINE DERIVATIVES FOR USE AS ANTIBACTERIAL AGENTS
YU68900A (en) Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to theat cancer
MXPA06000987A (en) Nicotinamide derivatives useful as pde4 inhibitors.
ES2095192A1 (en) Burn ointment
ATE468032T1 (en) METHOD FOR REDUCING ABERITY
ATE208202T1 (en) USE OF DIMETICON TO TREAT CONSTIPATION
DE69928282D1 (en) SUBSTITUTED 1,3,5-TRIAZINES AS HERBICIDES
SE0203237L (en) Methods and compositions for treating and preventing cell growth in smooth muscle